Serum-based biomarkers for psychiatric disorders;Serumbiomarker für psychiatrische Erkrankungen

Nervenarzt

Volumn 82, Issue 11, 2011, Pages 1395-1403

  Bahn, S ^a,b   Schwarz, E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Diagnosis; Psychiatrists; Regulatory authorities; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD; HUMAN; PSYCHIATRIST; SCHIZOPHRENIA;

BIOLOGICAL MARKERS; BLOOD PROTEINS; FORECASTING; GERMANY; HUMANS; MENTAL DISORDERS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 80755140522     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-011-3346-z     Document Type: Article

References (58)

1. Owens J (2006) Funding for accelerating drug development initiative critical. Nat Rev Drug Discov 5(4):271
2. Marson B (2007) Critical Path is on the road forward; FDA reports industry activity is high. Pink Sheet 69:29
3. Goodsaid F, Frueh F (2006) Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7(5):773-782 (Pubitemid 44225912)
4. Schwarz E, Guest PC, Rahmoune H et al (2011) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry (in press)
5. Laughren TP (2010) What's next after 50 years of psychiatric drug development: an FDA perspective. J Clin Psychiatry 71(9):1196-1204
6. DiMasi JA, Faden LB (2011) Competitiveness in follow-on drug R&D: a race or imitation? Nat Rev Drug Discov 10(1):23-27
7. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209-1223 (Pubitemid 41345943)
8. Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry 163(11):1905-1917 (Pubitemid 44807782)
9. Kashshai D, Mate B (1961) The effect of nicotinic acid on the temperature of the skin of patients with schizophrenia in different states. Zh Nevropatol Psikhiatr Im S S Korsakova 61:1688-1698
10. Vaddadi KS (1981) Niacin flushing and schizophrenia. Med Hypotheses 7(5):599-600 (Pubitemid 11090370)
11. Wilson DW, Douglass AB (1986) Niacin skin flush is not diagnostic of schizophrenia. Biol Psychiatry 21(10):974-977 (Pubitemid 16037306)
12. Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15(5):473-500
13. Desmedt C, Sperinde J, Piette F et al (2009) Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 18(1):22-29
14. Spadoni LR, McLean RB, Herrmann WL (1964) A rapid immunological test for the detection of early pregnancy. West J Surg Obstet Gynecol 72:92-97
15. Ball RH, Caughey AB, Malone FD et al (2007) First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 110(1):10-17 (Pubitemid 47015694)
16. Cronin M, Sangli C, Liu ML et al (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53(6):1084-1091 (Pubitemid 46867525)
17. Howey JE, Bennet WM, Browning MC et al (1989) Clinical utility of assays of glycosylated haemoglobin and serum fructosamine compared: use of data on biological variation. Diabet Med 6(9):793-796 (Pubitemid 20000311)
18. Shaffer D (1996) A participant's observations: preparing DSM-IV. Can J Psychiatry 41(6):325-329 (Pubitemid 26302843)
19. Cheniaux E, Landeira-Fernandez J, Versiani M (2009) The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology 42(5):293-298
20. Lovatt A, Mason O, Brett C, Peters E (2010) Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis 198(11):813-819
21. Scaglia F (2010) The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev 16(2):136-143
22. Yolken RH, Dickerson FB, Fuller Torrey E (2009) Toxoplasma and schizophrenia. Parasite Immunol 31(11):706-715
23. Tsuang MT (1975) Heterogeneity of schizophrenia. Biol Psychiatry 10(4):465-474
24. Gonzalez-Pinto A, Gutierrez M, Mosquera F et al (1998) First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 50(1):41-44 (Pubitemid 28338303)
25. Follette WC, Houts AC (1996) Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol 64(6):1120-1132 (Pubitemid 126505415)
26. Bertenshaw GP, Yip P, Seshaiah P et al (2008) Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(10):2872-2881
27. Gurbel PA, Kreutz RP, Bliden KP et al (2008) Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 155(1):56-61 (Pubitemid 350234773)
28. Delaleu N, Immervoll H, Cornelius J, Jonsson R (2008) Biomarker profiles in serum and saliva of experimental Sjogren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 10(1):R22
29. Domenici E, Wille DR, Tozzi F et al (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5(2):e9166
30. Fessel WJ, Solomon GF (1960) Psychosis and systemic lupus erythematosus: a review of the literature and case reports. Calif Med 92:266-270
31. Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94(9):3171-3182
32. Volp AC, Alfenas Rde C, Costa NM et al (2008) Inflammation biomarkers capacity in predicting the metabolic syndrome. Arq Bras Endocrinol Metabol 52(3):537-549
33. Muller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255(2):149-151 (Pubitemid 40558607)
34. Guest PC, Wang L, Harris LW et al (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15(2):118-119
35. Sato T, Hanyu H, Hirao K et al (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9):1626-1633
36. Baptista T, Rangel N, Fernandez V et al (2007) Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93(1-3):99-108 (Pubitemid 46839067)
37. Henderson DC, Fan X, Sharma B et al (2009) A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 119(6):457-465
38. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H (2006) Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry 60(8):889-891 (Pubitemid 44527889)
39. Santos LL, Morand EF (2009) Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 399(1-2):1-7
40. Burger-Kentischer A, Goebel H, Seiler R et al (2002) Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105(13):1561-1566 (Pubitemid 34297633)
41. Bruchfeld A, Carrero JJ, Qureshi AR et al (2009) Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med 15(3-4):70-75
42. Chung CP, Avalos I, Oeser A et al (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66(2):208-214 (Pubitemid 46226056)
43. Wajed J, Ahmad Y, Durrington PN, Bruce IN (2004) Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology (Oxford) 43(1):7-12 (Pubitemid 38088360)
44. De Hert M, Winkel R van, Van Eyck D et al (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2:14
45. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793-1801 (Pubitemid 44033299)
46. Steiner J, Walter M, Guest P et al (2010) Elevated S 100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15(1):3-4
47. Harris LW, Wayland M, Lan M et al (2008) The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 3(12):e3964
48. Prabakaran S, Swatton JE, Ryan MM et al (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(7):684-697, 643 (Pubitemid 38932173)
49. Uranova NA, Zimina IS, Vikhreva OV et al (2010) Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry 11(3):567-578
50. Rybakowski J, Weterle R (1991) Niacin test in schizophrenia and affective illness. Biol Psychiatry 29(8):834-836
51. Morrow JD, Awad JA, Oates JA, Roberts LJ 2nd (1992) Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 98(5):812-815
52. Smesny S, Klemm S, Stockebrand M et al (2007) Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 77(2):79-85 (Pubitemid 47539106)
53. Steiner J, Walter M, Wunderlich MT et al (2009) A new pathophysiological aspect of S 100B in schizophrenia: potential regulation of S 100B by its scavenger soluble RAGE. Biol Psychiatry 65(12):1107-1110
54. Seaton BE, Goldstein G, Allen DN (2001) Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. Neuropsychol Rev 11(1):45-67 (Pubitemid 33635921)
55. Schwarz E, Izmailov R, Spain M et al (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5:39-47
56. Riecher-Rossler A, Gschwandtner U, Borgwardt S et al (2006) Early detection and treatment of schizophrenia: how early? Acta Psychiatr Scand Suppl (429):73-80 (Pubitemid 43340893)
57. Fleeman N, Dundar Y, Dickson R et al (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenom J 11:1-14
58. Strakowski SM, Flaum M, Amador X et al (1996) Racial differences in the diagnosis of psychosis. Schizophr Res 21:117-124 (Pubitemid 26279233)